The number and genetic relatedness of transmitted/founder virus impact clinical outcome in vaginal R5 SHIV\textsubscript{SF162P3N} infection

Tsai et al.
The number and genetic relatedness of transmitted/founder virus impact clinical outcome in vaginal R5 SHIV<sub>SF162P3N</sub> infection

Lily Tsai<sup>1</sup>, Ivan Tasovski<sup>2,3</sup>, Ana Rachel Leda<sup>1</sup>, Mario PS Chin<sup>2,3</sup> and Cecilia Cheng-Mayer<sup>1*</sup>

**Abstract**

**Background:** Severe genetic bottleneck occurs during HIV-1 sexual transmission whereby most infections are initiated by a single transmitted/founder (T/F) virus. Similar observations have been made in nonhuman primates exposed mucosally to SIV/SHIV. We previously reported variable clinical outcome in rhesus macaques inoculated intravaginally (ivg) with a high dose of R5 SHIV<sub>SF162P3N</sub>. Given the potential contributions of viral diversity to HIV-1 persistence and AIDS pathogenesis and recombination between retroviral genomes increases the genetic diversity, we tested the hypothesis that transmission of multiple variants contributes to heightened levels of virus replication and faster disease progression in the SHIV<sub>SF162P3N</sub> ivg-infected monkeys.

**Results:** We found that the differences in viral replication and disease progression between the transiently viremic (TV; n = 2), chronically-infected (CP; n = 8) and rapid progressor (RP; n = 4) ivg-infected macaques cannot be explained by which variant in the inoculum was infecting the animal. Rather, transmission of a single variant was observed in both TV rhesus, with 1–2 T/F viruses found in the CPs and 2–4 in all four RP macaques. Moreover, the genetic relatedness of the T/F viruses in the CP monkeys with multivariant transmission was greater than that seen in the RPs. Biological characterization of a subset of T/F envelopes from chronic and rapid progressors revealed differences in their ability to mediate entry into monocyte-derived macrophages, with enhanced macrophage tropism observed in the former as compared to the latter.

**Conclusion:** Our study supports the tenet that sequence diversity of the infecting virus contributes to higher steady-state levels of HIV-1 virus replication and faster disease progression and highlights the role of macrophage tropism in HIV-1 transmission and persistence.

**Keywords:** Vaginal transmission, Transmitted/founder virus, Quasispecies complexity
routes [24,25]. Similar observations had been made in rhesus macaques (RMs) exposed intrarectally (ir) or intravaginally (ivg) to low-dose SIV and SHIV [26-29], and in depo-provera treated macaques exposed vaginally to a single supra-physiological dose of R5 SHIV [30], highlighting the effectiveness of the transmission bottleneck. Given the potential contributions of viral diversity to HIV-1 persistence and AIDS pathogenesis, the restriction in quasispecies population diversity in the recipient hosts upon HIV-1 transmission, in particular via vaginal exposure, could prove disadvantageous to viral persistence and disease induction in the new host. The initial process of fitness recovery therefore may require early and rapid diversification of the transmitted viruses to combat the evolving host selection pressures. This could be achieved through viral turnover of a highly infectious transmitted virus. Alternatively, since recombination between retroviral genomes is estimated to exceed the rate of mutation [31-34], and extensive recombination among HIV-1 quasispecies has been shown to contribute to viral diversity in infected patients [22,35], it is reasonable to hypothesize that transmission of multiple variants facilitates the generation of genetic variations and increase in viral fitness, leading to heightened levels of virus replication and rapid disease progression. We tested this hypothesis by investigating the population size and characteristics of the T/F viruses in R5 SHIVSF162P3N intravaginally infected macaques with variable clinical outcome.

Results
Variable disease outcome in macaques infected intravaginally with SHIVSF162P3N

We previously observed variable clinical outcome in rhesus macaques (RMs) infected intravaginally (ivg) with high dose R5 SHIVSF162P3N [36]. The animals were not synchronized with respect to the stage of the menstrual cycle before ivg challenge, and were inoculated with different doses (1,000 and 10,000 TCID50) and exposure frequencies (once or twice within the same day) using the same batch of virus stock (Table 1). Two ivg-inoculated macaques showed transient viremia (Figure 1A), while establishment of chronic infection in eight (Figure 1B) and rapid disease progression in four was observed (Figure 1C). A dose-dependency in ivg infection outcome was not observed in this small cohort of animals studied. Moreover, a paradoxical inverse association between exposure frequencies and clinical outcome was noted: a rapid progressor (RP) phenotype was absent in the four macaques receiving two high dose virus inoculations four hours apart, with animals either showing transient viremia (AH94, DE37) or slow disease progression (CF18, FH84). This inverse association between exposure frequencies and clinical outcome could not be explained by MHC class I and TRIM5α genetic polymorphisms or selection for particular T/F viruses ([36]; this study), and is seen only with intravaginal and not with intrarectal challenge, raising the possibility of differential anatomical host response to the virus dose or nonviral constituents present in the virus supernatants that could potentially influence viral infectivity and early infection events. Studies in additional animals will be required to address this. As anticipated, peak and cumulative viral load up to the time of euthanasia or over a one-year infection period were significantly higher in the RPs than the chronic progressors (CPs) (p = 0.0162 and p = 0.004 respectively; Figure 2). The four RPs succumbed to AIDS within 30 weeks of infection in the absence of seroconversion, while all eight chronic progressors and one of the transient viremic (TV) animals (AH94) seroconverted.

| Clinical status       | Animal | Challenge dose; frequency | Time to necropsy (weeks) |
|-----------------------|--------|---------------------------|--------------------------|
| Transient Viremic     | AH94   | 10,000; 2X                | 54                       |
|                       | DE37   | 10,000; 2X                | 59                       |
| Chronic progressor    | CG45   | 1,000; 1X                 | 59                       |
|                       | CG63   | 1,000; 1X                 | 59                       |
|                       | FR25   | 10,000; 1X                | 129                      |
|                       | FV44   | 10,000; 1X                | 53                       |
|                       | GH62   | 10,000; 1X                | 53                       |
|                       | GR56   | 10,000; 1X                | 53                       |
|                       | CF18   | 10,000; 2X                | 52*                      |
|                       | FH84   | 10,000; 2X                | 104*                     |
| Rapid progressor      | DG17   | 1,000; 1X                 | 22*                      |
|                       | GC70   | 1,000; 1X                 | 24*                      |
|                       | EI77   | 10,000; 1X                | 27*                      |
|                       | EL48   | 10,000; 1X                | 17*                      |

*AIDS-related euthanasia.
at 4–6 week post-infection (wpi). Seven of eight CP and both TV animals remained AIDS-free after one year of infection. The difference in survival between the RPs and CPs is statistically significant (p <0.001; Figure 2).

Faster disease progression correlates with increase number and complexity of transmitted founder viruses

Consistent with our preliminary findings in the CP FH84 and TV DE37 [36], phylogenetic tree analysis of env V3-V5 sequences in the first viral RNA positive plasma samples of the ivg-infected animals shows that those from the TV, CP and RP macaques intermingled (Figure 3A), suggesting that the differences in viral replication and disease progression among these three groups of animals cannot be explained by transmission/infection with specific genotypic variants. Because conventional nested PCR and cloning was employed to characterize most env sequences, we performed single genome amplification (SGA) and direct sequencing of uncloned env amplicons from early plasma of two infected macaques (GR56, GH62) to address the concerns that the results observed may be due to *Taq*-induced PCR errors. Data showed that the env sequences obtained with the SGA approach are similar to those obtained by conventional PCR (Figure 3B), consistent with reports that bulk sequencing captures a measure of population diversity similar to that determined by SGA [37].

Primary infection with multiple HIV variants from a single source as determined by heteroduplex mobility tracking of proviral DNA had been suggested to accelerate rates of disease development in human [19], but the degree of population diversity and the number of transmitted variants were not investigated in this study. Accordingly, we determined the number of transmitted/founder viruses in the ivg-infected macaques. Consistent with reports in HIV transmission in human and SIV transmission in macaques [17,23,27,29,38], vaginal transmission of SHIVSF162P3N in RMs is characterized by a genetic bottleneck, with a single or limited number of viral variants transmitted despite the use of high inoculum doses and increased frequency of exposure in several animals. Enumeration of the number of transmitted variants by Highlighter plot analysis shows however that more variants were transmitted in the RP than in the CP or TV macaques (Figure 4). Both TV animals were infected with a single variant, with 1–2 transmitted variants found in CPs and 2–4 variants in the four...
RP monkeys. The difference in the number of transmitted variants between the latter two groups of animals approached statistical significance (p = 0.0727). Furthermore, pairwise distance analysis shows that T/F variants are more genetically diverse in the RP than in the CP and TV animals (Figure 5). Overall diversity, expressed as the percent of the average pairwise difference in T/F env V3-V5 sequences is greater in the RP than the CP and TV. Mean percentage sequence variation among the T/F viruses of TV is 0.050%, and this increases to 0.549% in the CPs and 1.105% in the RPs, with statistically significant differences among the groups that support a positive correlation between the heterogeneity of the infecting virus population and subsequent clinical outcome (p < 0.0001; Figure 5B). Table 2 summarizes the estimated number and genetic diversity of T/F variants in R5 SHIVSF162P3N ivg-infected macaques, showing that virus replication and disease progression in R5 SHIVSF162P3N ivg-infected macaques are associated with the population size and env sequence diversity of the transmitter/founder (T/F) viruses.

T/F viruses in chronic progressors are more macrophage-tropic than those in rapid progressors

HIV-1 mucosal transmission is primarily associated with CD4+ T cell tropism and CCR5 use, with lower levels of replication in monocyte-derived macrophages (MDM) compared to CD4+ T cells for subtype C and B transmitted viruses [24,39]. Because infected macrophages are long-lived [40,41] and resistant to CTL suppression [42,43], and HIV-1 particles within infected macrophages are protected from neutralization antibodies [44-46] and can be transmitted efficiently to T cells [47,48], we compared infection of PBMCs and MDMs mediated by representative Envs from each of the T/F clusters in six of eight CP and all four RP macaques to determine if the latter plays a role in post-acute infection. Results showed no significant difference in the ability of the Envs from the two groups of infected macaques to mediate entry into mitogen-stimulated PBMCs that express high amounts of CD4 and CCR5 (Figure 6A). In contrast, while a wider range of macrophage tropism was seen in the CPs than in the RPs, T/F viruses in RPs overall are less macrophage-tropic than the CPs, with the difference being statistical significance (p = 0.0383; Figure 6B).

Discussion

By characterizing a cohort of R5 SHIVSF162P3N ivg-infected macaques that display distinct clinical outcomes, here we show that a specific viral variant in the challenge stock was not consistently transmitted by intravaginal inoculation and the relative dose of the inoculum did not correlate grossly with the number of variants transmitted. Transmission of multiple and genetically diverse viral variants from the inoculum however is associated with higher peak and chronic viral load as well as accelerated rates of disease development. Moreover, macrophage tropism of the transmitted/founder
Figure 4 Highlighter plot and hamming distance analyses of T/F env in R5 SHIV$_{SF162P3N}$ ivg-infected macaques. Data for env V3-V5 sequences from representative transiently viremic (TV; AH94), chronically-infected (CP; FR25, GH62) or rapidly-progressing (RP; EI77, DG17, EL48) macaques is shown. Positions of nucleotide base transitions and transversions in the highlighter plots are indicated by short, colored coded bars. Colors are as follows: A: green, T: red, G: yellow, C: blue and gaps: grey. Tics that are bracketed represent G-to-A changes while those in circles represent G-to-A changes in a sequence consistent with an APOBEC signature. The number of identifiable T/F viruses is listed on the left.

Figure 5 Pairwise distance analysis of T/F env in R5 SHIV$_{SF162P3N}$ ivg-infected macaques. Data for env V3-V5 sequences from all individual macaque (A) and among the TV (in green), CP (in blue) and RP (in red) groups (B) is shown. The sampling time (wpi) for each animal in the three groups is indicated in (A). The lines in bold in (A) and (B) represent the mean pairwise distance for each individual animal or group, respectively, with an asterisk (*) in (B) indicating statistical significance (p < 0.05).
virus contributes to the establishment of a persistent infection.

A correlation between peak viral load and the number of transmitted viruses was observed for macaques infected intrarectally with SIVsmE660 and SIVmac251 [26], a finding that is recapitulated here in our R5 SHIV vaginal transmission model in which SHIVSF162P3N-infected RPs had the highest peak viremia and numbers of T/F viruses. Furthermore, co-infection with divergent HIV-1 subtypes has been associated with more severe disease progression in human [16,18], and heteroduplex tracking assay analysis showed that women who acquired multiple variants from a single source had a significantly higher chronic viral load and lower CD4+ T cell count compared to women who were infected with a single viral genotype [19]. Our study extends these early observations by showing that the number of variants, sequence diversity and macrophage tropism of the T/F populations also contribute to higher steady-state levels of HIV-1 virus replication and faster disease progression. Since viral diversity was examined, in most cases, at the first vRNA positive time point (1–2 weeks post-challenge), the finding of higher levels of acute viremia (2–3 wpi) in monkeys with genetically diverse viruses is most likely due to transmission of multiple envelope genotypes and not the result of viral turnover of highly infectious transmitted viruses. Indeed, we did not find statistically significant differences in the ability of

| Clinical status | Animal | Sampling time point (wpi) | vRNA (copies/ml plasma) at time of sampling | No. of env sequences analyzed | No. of identified T/F viruses | Mean env diversity |
|-----------------|--------|---------------------------|------------------------------------------|-------------------------------|-------------------------------|--------------------|
| Transient Viremic | DE37   | 2                         | 2,959                                    | 44                            | 1                             | 0.0004             |
|                 | AH94   | 3                         | 74,929                                   | 28                            | 1                             | 0.0006             |
| Chronic Progressors | FR25   | 1                         | 2,458                                    | 21                            | 1                             | 0.0005             |
|                 | CF18   | 1                         | 1,413                                    | 19                            | 1                             | 0.0006             |
|                 | CG63   | 2                         | 61,996,000*                              | 20                            | 1                             | 0.0030             |
|                 | FV44   | 2                         | 39,494                                   | 30                            | 2                             | 0.0030             |
|                 | FH84   | 2                         | 36,073,000*                              | 49                            | 2                             | 0.0032             |
|                 | GH62   | 2                         | 3,902,206*                               | 59*                           | 2                             | 0.0034             |
|                 | CG45   | 1                         | 7,140                                    | 24                            | 2                             | 0.0126             |
|                 | GR56   | 3                         | 1,186,674*                               | 58*                           | 2                             | 0.0176             |
| Rapid Progressors | GC70   | 2                         | 67,857,860*                              | 24                            | 2                             | 0.0052             |
|                 | DG17   | 1                         | 10,844                                   | 29                            | 3                             | 0.0122             |
|                 | EL48   | 1                         | 48,548                                   | 42                            | 4                             | 0.0130             |
|                 | EI77   | 1                         | 17,119                                   | 38                            | 2                             | 0.0138             |

*p indicates time of peak viremia; # designates the two animals (GH62, GR56) where both SGA and conventional cloning was performed to generate the env sequences: 19 SGA and 40 cloning sequences for GH62 and 27 SGA and 31 cloning sequences for GR56 were analyzed. All the analyses were performed with a 660 bp env V3-V5 sequences.

Figure 6 PBMC (A) and MDM tropism (B) of T/F Envs. Pseudotype viruses bearing T/F Envs from six CP (in blue) and four RP (in red) macaques are tested for their ability to infect peripheral blood mononuclear cells (PBMCs) and monocyte-derived macrophages (MDMs). To control for differences in viral entry, infectivity in macrophages was normalized to that achieved in PBMCs from the same donor. Data shown are for individual Env clones (2–5) from each animal and is the average of at least two independent experiments. The lines represent the median value for each group and an asterisk (*) indicates statistical significance (p < 0.05). NS, not significant; RLU, relative light units.
T/F Envs from the CP and RP macaques to mediate entry into mitogen-stimulated PBMCs that would be suggestive of differences in the infectiousness of their T/F viruses. Collectively our data establishes a role of T/F quasispecies diversity in HIV-1 pathogenesis.

The number of T/F variants in our study is likely to be underestimated, since only the gag120 V3-V5 sequences were analyzed. Nonetheless, an association between transmission of diverse population of SHIV variants, higher viral burden and rapid disease progression was seen, supporting a scenario whereby viral quasispecies that are more fit and capable of escaping early host selective pressures are generated through recombination and cooperative interactions between the transmitted variants. Multiple variant transmission represents a significant fraction of transmission events: 24% and 22% for subtype B and C sexually infected men and women, respectively [17,23]. Factors that influence transmission of diverse viruses however are unclear. Biological factors such as gender, viral subtypes, routes of transmission and the presence of STDs can affect multiple variant transmission frequencies. The impact of these factors however is controlled in our study where female macaques were infected via the same route and with the same virus stock in the absence of STDs. Multivariant transmission susceptibility could also be influenced by age, vaginal flora and timing of the menstrual cycle before challenge [49], parameters that were not controlled for in our small cohort study. Moreover, polymorphisms in alpha-interferon (IFN-α) induced restriction factors such as TRIM5-α, APOBEC3G, tetherin and MX2 that affect their expression levels and/or functions may also play a role [50-52]. Indeed, a recent study showed that compared to chronic viruses, subtype B but not subtype C T/F viruses in human are more resistant to IFN-α [53]. However, we did not find any differences in the IFN-α sensitivity of HIV-1 NL4-3 reporter genome pseudotyped with T/F Envs from the CP and RP rhesus (unpublished observations). Studies using full-length infectious T/F molecular clones and in a larger cohort of ivg-infected macaques would be needed to determine the effect of varying biologic and innate host factors in multivariant transmission frequency.

In agreement with a recent report that all T/F viruses replicated in MDM to various levels [54], our study shows variability in the ability of T/F Envs to function with primary macrophages, with those derived from CP macaques mediating more efficient entry than the ones from RP rhesus. These immune cells play a duplicitous role during early HIV-1 infection. Macrophages in the vaginal mucosa have been shown to be productively infected [55], secreting cytokines to recruit CD4+ T cells at the sites of viral entry to fuel the infection [56]. Moreover, infected macrophages possess potent immune evasion mechanisms, are long-lived viral reservoirs and are particularly efficient at transmitting the virus to new CD4+ T cells [57]. At the same time, as antigen presenting cells, macrophages can take up and process virus for priming of CD4+ and CD8+ T cells to initiate and orchestrate antiviral humoral and cellular immune response. Thus, it is conceivable that the inability of the RP macaques to control virus infection is due in part to inefficient macrophage infection of the T/F viruses which hampered the development of effective adaptive immune responses. Conversely, efficient macrophage infection by T/F viruses in the CP rhesus promotes not only viral transmission and spread, but T and B cell responses to reduce acute viremia, leading to the onset of a persistent chronic infection.

Conclusions
Our study established the view that the population size and genetic complexity of the transmitted virus population impact the subsequent course of R5 SHIV vaginal infection and highlights the role of acute quasispecies diversity and macrophage tropism in HIV-1 associated pathogenesis. We posit that increased complexity of the T/F populations coupled with inefficient macrophage infection hampers the initiation and orchestration of adaptive immune responses and contributed to the inability of the R5 SHIVSF162P3N ivg-infected RP macaques to control viral replication. It will be of interest to characterize and compare the occurrence, frequency and kinetics of retroviral recombination in CP and RP macaques that are infected with multiple variants to assess the effect of T/F diversity on viral evolution, fitness and host immune response.

Methods
Ethical statement
This work used blood from SHIV infected macaques housed at the Tulane National Primate Research Center (TNPRC) in accordance with the animal Welfare Act and Guide for the Care and Use of Laboratory Animals. TNPRC is accredited by the Association and Assessment and Accreditation of Laboratory Animal Care (AAALAC #00594). The OLAW animal welfare assurance number for TNPRC is A4499-01 and the USDA registration number is 72-R-002. All procedures were performed on anesthetized animals and post-operative analgesics were administered as needed in accordance with the Tulane IACUC approval.

Cells
293 T cells were maintained in DMEM supplemented with 10% fetal bovine serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (complete medium). Human peripheral mononuclear cells (PBMCs) were prepared by Ficoll gradient centrifugation, stimulated...
with phytohemagglutinin (PHA, 3 μg/ml; Sigma, St. Louis, MO) in RPMI medium containing 10% FCS, penicillin, streptomycin, L-glutamine and 20 U/ml interleukin-2 (Novartis, Emeryville, CA). Monocytes were enriched by centrifugation of PBMCs through a 40% percoll cushion followed by plastic adherence, and cultured in RPMI 1640 medium supplemented with 10% FCS, 5% human AB serum and 25 ng/ml GM-CSF (Invitrogen, Carlsbad, CA) for 5–7 days to allow for differentiation into macrophages.

**Plasmid constructs and pseudotyped virus production**

For expression of envelope glycoproteins (Env), viral RNA was prepared from 0.5 – 1 ml plasma using a commercially available RNA extraction kit (Qiagen, Chatsworth, CA) followed by reverse-transcription (RT) with Superscript III (Invitrogen) and random hexamer primers (Amersham Pharmacia, Piscataway, NJ). Full-length gp160 coding sequences were amplified from cDNA by single genome amplification (SGA) or by conventional PCR. For SGA, cDNA was titrated by endpoint dilution and a single copy obtained in a two-step nested PCR procedure using Platinum Taq High Fidelity polymerase (Invitrogen) and the primers SH50 (5′-TAGGCGCTGGAAAGCATCCAG GAAATCGCCTA -3′) and SH51 (5′-TCCAGTCCCC CTTTTCATTTTAAAGG -3′), and SH43 (5′-AGA CAGAATTCATGAGAGTGAAGGGGATCAGGAAG -3′) and SH44 (5′-AGAGGGGATCCTTATAGCGAACCC TTCAAGGCCCT -3′) for the first and second rounds of PCR, respectively. The same primers were used for conventional nested PCR. Amplicons were subcloned into the pCAGGS vector and sequenced, and trans-complementation assay was then used to generate luciferase reporter viruses capable of only a single round of replication. Briefly, Env expression plasmid and the NL4.3LucE-R + vector were cotransfected with polyethylenimine (PEI, Polyscience, WI). Entry, as quantified by luciferase activity, was measured from 0.5 ml luciferase activity according to the manufacturer (Promega, Madison, WI). Entry, as quantified by luciferase activity, was measured from 0.5 ml luciferase activity according to the manufacturer (Promega, Madison, WI). Entry, as quantified by luciferase activity, was measured from 0.5 ml luciferase activity according to the manufacturer (Promega, Madison, WI).

**Virus infectivity**

For assessment of entry efficiency into primary cells, 10^5 and 10^6 human PBMCs and macrophages respectively were infected in duplicate with 5 ng p24 Gag equivalent of the indicated pseudotype viruses in each well of a 96-well plate. Infected cells were cultured for 72 h at 37°C, at which time the cells were harvested, lysed and processed for luciferase activity according to the manufacturer’s instructions (Luciferase Assay System; Promega, Madison, WI). Entry, as quantified by luciferase activity, was measured with an MLX microtiter plate luminometer (Dynex Technologies, Inc., Chantilly, VA). To control for differences in Env entry efficiencies, infectivity in macrophages was expressed as a ratio of the infectivity for these cells compared to the infectivity in PBMCs from the same donor.

**Phylogenetic and Highlighter Plot analysis of env viral sequences**

DNA sequences encompassing env V3 to V5 region of gp120 (660 bp) were aligned by Clustal W [58], using SF162 strain as reference. A codon-based alignment was also performed in order to remove sequencing errors, gaps and homopolymeric regions. Neighbor-joining phylogenetic trees were generated by MEGA 5.2.2 [59], using the Jukes Cantor model of evolution [60], with a gamma distribution of site-to-site rate variation as estimated by the FindModel tool from the Los Alamos National Laboratory (LANL) HIV Database (http://hiv.lanl.gov). Gaps but not hypermutated sequences were excluded from the analyses. Viral sequences were visually assessed using the Highlighter tool at the LANL HIV Database.

**Hamming and pairwise distance analyses**

DNA sequences encompassing the V3 to V5 regions of env were first aligned by ClustalW [58]. Consensus sequences were then generated with the Consensus Maker tool provided by the Los Alamos National Laboratory (LANL) HIV Database (http://hiv.lanl.gov). Best fitting Poisson distributions and Hamming distance frequency distributions were then computed utilizing the Poisson-Fitter tool found at http://hiv.lanl.gov [61], whereby no APOBEC correction was applied and mutation rates were adjusted such that the time estimates since the most recent common ancestor best matched the time of sequencing for each animal. Lastly, pairwise distances were calculated from ClustalW-aligned sequences using MEGA 5.2.2 [59].

**Statistical analysis**

All statistical analyses were performed using GraphPad Prism (version 6.0; GraphPad Software, San Diego, CA). Differences in time to AIDS onset between groups were assessed using the log-rank test, while differences among groups in peak viremia, cumulative viral load, pairwise distance and cell tropism were examined using the Mann–Whitney two-tailed t tests. A P value of <0.05 was considered to be statistically significant.

**Competing interests**

The authors declare no competing interests.

**Authors’ contributions**

LT performed the experiments and data analysis. IT and ARL contributed to the analysis and interpretation of the study. CCM and MPSC designed the study, interpreted the data and wrote the manuscript with help and approval from all authors.
References
1. Eigen M: Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften 1971, 58:465–523.
2. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S: Rapid evolution of RNA genomes. Science 1982, 215:1577–1585.
3. Goodenow M, Huett T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S: The accuracy of reverse transcriptase
4. Steinhauer DA, Holland JJ: Rapid evolution of RNA viruses. Proc Natl Acad Sci U S A 1982, 79:2344–2352.
5. Preston BD, Poiesz BJ, Loeb LA: Increased fidelity reduces poliovirus fitness and preferred nucleotide substitutions. J Virol 1989, 63:1971–1973.
6. Weber J, Grosse F: Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural DNA. Nucleic Acids Res 1989, 17:1379–1393.
7. Hu WS, Temin HM: Retroviral recombination and reverse transcription. Science 1990, 250:1227–1233.
8. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R: Intrapatient diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006, 439:344–348.
9. Pfeiffer JK, Kirkegaard K: Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 2005, 1:e11.
10. Plowes BJ, Hoofnagle JH, Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hase M, Cohen MS, Karim SA, Haynes BF, Shaw GM: Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241–6247.
11. Liu J, Keefe BF, Li H, Leam GH, Hraber P, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya JV, i n c a t e o f h a m m o d i c a l l y r e n e w i n c h e s s m e a n s t e p p o s e s o f t h e i m m u n o d e f i c i e n t s y s t e m. J Virol 2007, 81:4675–4678.
12. Mani J, Gilbert P, Sankale JL, Eisen G, Mboup S, Kanki PJ: Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02-A/G-IbNG infection. J Virol 2002, 76:10406–10412.
13. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Pioguard P, Doyle LA, Cavacini L, Veazey RS, Moore JP: Low-dose rectal inoculation of rhesus macaques with SIVmac251 recapitulates human mucosal infection by HIV-1. Proc Natl Acad Sci U S A 2009, 106:1117–1134.
14. McNeary T, Hornickova Z, Markham R, Birdwell A, Ares M, Saah A, Ratner L: Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A 1992, 89:10247–10251.
15. Bordera AV, Lorenzo-Redondo R, Pernas M, Casado C, Alvaro T, Domingo E, Lopez-Galindez C: Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One 2010, 5:e10319.
16. Gottlieb GG, Nickle DC, Jensen MA, Wong JK, Grobler J, Li F, Liu SL, Rademeyer C, Lear GH, Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI: Dual HIV-1 infection associated with rapid disease progression. Lancet 2004, 363:619–622.
17. Abraham MR, Anderson JA, Giorgi EE, Seoighe C, Missana K, Ping LH, Athreya GA, Teurismit FK, Keefe BF, Wood N, Salazar-Gonzalez JF, Hnattachayaa T, Chu H, Hofmann I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hase M, Cohen MS, Karim SA, Haynes BF, Shaw GM, Hraber P, Bolten KT, Sninsky J, Wain-Hobson S, Luintel NV: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552–7557.
18. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Chohan BH, Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R: Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 subtype C-infected individuals with multiple transmitted/founder HIV-1. CROI 2013, 3/2013.
19. Keefe BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pharm KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei W, Jiang C, Kiehlir JL, Gao F, Alexander JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Bush MP, Cohen MS, Monteforti DC, Haynes BF, Gaschen B, Athreya GG, Lee HY: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. J Virol 2007, 81:1000890.
20. Li H, Bar Ki J, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Leam GH, Morgan CJ, Schumacher JF, Hraber PF, Giorgi EE, Bhattacharya T, Korbett BT, Persello AS, Erion J, Cohen MS, Hicks CB, Haynes BF, Markowitz M, Keefe BF, Bah NH, Shaw GM: High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010, 6:e1000890.
21. Jin J, Shi PY, Ebel GD: Genome-wide analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection. J Virol 2011, 85:10332–10345.
22. Stone M, Keele BF, Ma ZM, Bailey E, Dutra J, Hahn BH, Shaw GM, Miller CJ: A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010, 84:7083–7095.
23. Varela M, Landskron L, Lai RPI, McKinley TJ, Bogers WM, Verschoor EJ, Berkhout B, Ploegh HL: Mutation of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: implications for challenge dose selection. Proc Natl Acad Sci U S A 2011, 108:11181–11186.
24. Hu WS, Temin HM: Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidly and high rate of genetic recombination. Proc Natl Acad Sci U S A 1990, 87:1556–1560.
25. Liu J, Keefe BF, Li H, Keating S, Noris PJ, Carville A, Mansfield KG, Tomaras GD, Haynes BF, Kolobkin-Gal D, Lelkin NL, Hahn BH, Shaw GM: Low-multiplicity simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010, 84:10406–10412.
26. Burton DR, Hessell AJ, Keefe BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Vezays R, Moore JS: Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011, 108:11181–11186.
36. Shakirzayeva M, Tsai L, Ren W, Gettie A, Blanchard J, Cheng-Mayer C: Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol 2012, 86:9432–9442.

37. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, Chappey J, Manke C, Coffin JM: Comparison of standard PCR-cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods 2010, 168:114–120.

38. Greener JI, Miller CJ, Lu D, Dalley PJ, Lu FX, Kunstrman KJ, Wolinsky SM, Mathias ML: Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques. J Virol 2001, 75:3753–3765.

39. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learm GH, Giorgi EE, Li H, Decker JM, Wang S, Bailla J, Kraus MH, Parrish NF, Shav KS, Guffey MB, Bar JI, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Haber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH: Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273–1289.

40. Cassol E, Alfonso M, Biwas P, Polli G: Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol 2006, 80:1018–1030.

41. Sharova N, Swinger C, Sharkey M, Stevenson M: Macrophages archive HIV-1 virions for dissemination in trans. EMBO J 2005, 24:2481–2489.

42. Schutten M, van Baalen CA, Guillon C, Huismen RC, Boers PH, Sintrincoelas K, Grutes RA, Osterhaus AD: Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. J Virol 2001, 75:2706–2709.

43. Vojnov L, Martins MA, Bean AT, de Santana MG V, Sacha JB, Wilson NA, Bonaldo MC, Galler R, Stevenson M, Watkins DI: The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol 2012, 86:4682–4687.

44. Kopenpersteiner H, Banning C, Schneider C, Hohenberg H, Schindler M: Macrophage internal HIV-1 is protected from neutralizing antibodies. J Virol 2012, 86:2826–2836.

45. Abele IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Ruster P, Tikola A: Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 2012, 8:e1002639.

46. Chu H, Wang JJ, Qi M, Yoon JJ, Wen X, Chen X, Ding L, Spearman P: The intracellular virus-containing compartments in primary human macrophages are largely inaccessible to antibodies and small molecules. PLoS One 2012, 7:e35297.

47. Groth F, Welch S, Sattentau QI: Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 2008, 111:4660–4663.

48. Gousses K, Ablan SD, Coren LV, Omo A, Soheilian F, Nagashima K, Ott DF, Freed EO: Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog 2008, 4:e1000151.

49. Powers KA, Poole C, Pettit AE, Cohen MS: Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008, 8:553–563.

50. Yan N, Chen ZJ: Intrinsic antiviral immunity. Nat Immunol 2012, 13:214–222.

51. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, Barclay WS, Schulz R, Malim MH: Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502:559–562.

52. Kane M, Yadav SS, Bitzgeja J, Kutila SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD: Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013, 502:559–562.

53. Parrish NF, Gao F, Li H, Giorgi EE, Barjian HJ, Parrish EH, Zajic L, Yerly SS, Decker JM, Kamar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP Jr, Bjorkman PJ, Wilen CB, Doms RW, O’Haren JG, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD: Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Proc Natl Acad Sci U S A 2013, 110:6626–6633.

54. Ochsenbauer C, Edmonds TG, Ding H, Kelle BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattuck R, Haynes BF, Shaw GM, Hahn BH, Kappes JC: Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 2012, 86:2715–2728.

55. Shen RRH, Clements RH, Nock U, Huff G, Birczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD: Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol 2009, 83(7):3258–3267.

56. Herbein G, Gras G, Khan KA, Abbas W: Macrophage signalling in HIV-1 infection. Retrovirology 2010, 7:34.

57. Sattentau Q: Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008, 6:815–826.

58. Thompson JD, Higgins DJG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22:4673–4680.

59. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731–2739.

60. Jukes TH, Cantor CR: Evolution of protein molecules. In Mammalian protein metabolism. Edited by HH M. New York: Academic Press; 1969:1–132.

61. Giorgi EE, Funkhouser B, Atreya G, Perelson AS, Kotler BT, Bhattacharya T: Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Infectious 2010, 11:532.